BC
ACRS icon

Bridgefront Capital’s Aclaris Therapeutics ACRS Stock Holding History

Bridgefront Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-21,938
Closed -$177K – 430
2023
Q1 		$177K Buy
+21,938
New +$278K 0.11% 356

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bridgefront Capital's ACRS Position: Q2 2023 in Review

Bridgefront Capital sold out of Aclaris Therapeutics (ACRS) in Q2 2023, closing a stake of 21,938 shares — an estimated $177K sold.

Bridgefront Capital first reported a position in ACRS in Q1 2023 and held it in 1 quarter. The position peaked at $177K in Q1 2023. 133 funds tracked by Wall St. Rank hold ACRS as of Q2 2023.

  • Bridgefront Capital reported no remaining Aclaris Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Bridgefront Capital sold 21,938 Aclaris Therapeutics shares in Q2 2023, an estimated $177K.
  • Bridgefront Capital first reported a position in Aclaris Therapeutics in Q1 2023 and held it in 1 quarter.
  • Bridgefront Capital's Aclaris Therapeutics position peaked at $177K in Q1 2023.
  • 133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2023.

Based on Bridgefront Capital's 13F filing for Q2 2023, filed 14 Aug 2023.